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PRACTICE
GUIDELINES
Management of diabetes from preconception to the
postnatal period: summary of NICE guidance
The Guideline Development Group
Why read this summary?
Diabetes in pregnancy is associated with risks to the
woman (for example, higher rates of miscarriage, pre-
eclampsia, and preterm labour) and to the developing
fetus and baby (for example, higher rates of congenital
malformations, macrosomia, birth injury, and perina-
talmortality).1 2This article summarises themost recent
guidance from the National Institute for Health and
ClinicalExcellence (NICE)onhow tomanagediabetes
and its complications from preconception to the
postnatal period.3
Recommendations
NICE recommendations are based on systematic
reviews of best available evidence. When minimal
evidence is available, recommendations are based on
the guideline development group’s opinion of what
constitutes good practice. Evidence levels for the
recommendations are in the longer version of this
article on bmj.com.
Preconception information for women with pre-existing
diabetes
 From adolescence onwards, advise women about
the importance of avoiding unplanned preg-
nancy.
 Inform women and their families about how
diabetes affects pregnancy and how pregnancy
affects diabetes (box).
 Offer preconception care and advice to women
who are planning to become pregnant before they
discontinue contraception; inform them that
establishing good glycaemic control before con-
ception and continuing throughout pregnancy
reduces—but does not eliminate—the risks of
miscarriage, congenital malformation, stillbirth,
and neonatal death.
 Offer a structured education programme (such as
“dose adjustment for normal eating” (DAFNE)
for type 1 diabetes, “diabetes education and self
management for ongoing and newly diagnosed”
type 2 diabetes (DESMOND), or X-PERT for
type 2 diabetes) as soon as possible to women
who are planning to become pregnant (unless
they have already attended one).
Glycaemic control before and during pregnancy
 Advise women with pre-existing diabetes who are
planning to become pregnant to keep their HbA1c
concentration below 6.1% if this is safely achiev-
able; reassure women that any reduction in
HbA1c towards the target of 6.1% is likely to
reduce the risk of congenital malformations;
women whose HbA1c is above 10% should be
strongly advised to avoid pregnancy.
 Offer monthly measurement of HbA1c to women
with pre-existing diabetes who are planning to
become pregnant; do not use HbA1c routinely for
assessing glycaemic control in the second and
third trimesters of pregnancy.
 Agree individualised targets for self monitoring of
blood glucose concentration before and during
pregnancy, taking into account the risk of
hypoglycaemia; advise pregnant women with
diabetes to keep their fasting blood glucose
between 3.5 mmol/l and 5.9 mmol/l and their
one hour postprandial blood glucose below
7.8 mmol/l if this is safely achievable.
The safety of medications for diabetes and its
complications before and during pregnancy
 Metformin may be used for women with pre-
existing diabetes as an adjunct or alternative to
insulin in the preconception period and during
pregnancy; discontinue all other oral hypogly-
caemic agents before pregnancy and substitute
with insulin.
 The rapid acting insulin analogues aspart and
lispro are safe to use during pregnancy; isophane
insulin is the first choice for long acting insulin
during pregnancy.
 Discontinue angiotensin converting enzyme inhi-
bitors and angiotensin II receptor antagonists
before pregnancy or as soon as pregnancy is
confirmed; substitute with alternative anti-
hypertensive agents suitable for use during
pregnancy.
This is one of a series of BMJ
summaries of new guidelines,
which are based on the best
available evidence; they will
highlight important
recommendations for clinical
practice, especially where
uncertainty or controversy exists.
Further information about the
guidance, a list of members of the
guideline development group, the
supporting evidence statements,
and additional references are in
the longer version of this article on
bmj.com.
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 Discontinue statins before pregnancy or as soon
as pregnancy is confirmed.
Management of diabetic emergencies and complications
during pregnancy
 Advise women with insulin treated diabetes of the
risks of hypoglycaemia and of hypoglycaemia
unawareness during pregnancy (particularly in
the first trimester); provide a concentrated
glucose solution (and glucagon for women with
type 1 diabetes) and advise women and their
partners or other family members on their use.
 Exclude diabetic ketoacidosis as a matter of
urgency in women with type 1 diabetes who
become unwell during pregnancy; admit women
who are suspected of having diabetic ketoacidosis
immediately for level 2 critical care, where they
can receive medical and obstetric care.
 Offer retinal and renal assessment to women with
pre-existing diabetes before and during preg-
nancy because diabetic retinopathy may worsen
during pregnancy and diabetic nephropathy is
associated with adverse pregnancy outcomes
(such as intrauterine growth restriction, pre-
eclampsia, and preterm birth).
Gestational diabetes
 Use risk factors (raised body mass index, pre-
vious macrosomic baby, previous gestational
diabetes, family history of diabetes, and family
origin with a high prevalence of diabetes) to
decide which pregnant women to test for gesta-
tional diabetes. In these women test for gesta-
tional diabetes using a two hour 75 g oral glucose
tolerance test (OGTT) and the World Health
Organization’s diagnostic criteria for gestational
diabetes. In women who have had gestational
diabetes in a previous pregnancy, offer early self
monitoring or an OGTT at 16-18 weeks and a
further OGTT at 28 weeks if the results are
normal; in women with any of the other risk
factors for gestational diabetes offer an OGTT at
24-28 weeks. Do not screen using fasting plasma
glucose, random blood glucose, glucose challenge
test, or urine analysis for glucose.4
 Inform women with gestational diabetes about the
effects of gestational diabetes on pregnancy (box);
tell them that good glycaemic control throughout
pregnancy will reduce the risk of fetal macrosomia,
trauma during birth (to themselves and the baby),
induction of labour or caesarean section, neonatal
hypoglycaemia, and perinatal death; and instruct
them in self monitoring of blood glucose. Targets
for blood glucose control are the same as for women
with pre-existing diabetes.
 Consider hypoglycaemic therapy if diet and exer-
cise fail to maintain blood glucose targets during a
period of one to two weeks; also consider hypogly-
caemic therapy if ultrasound investigation suggests
incipient fetal macrosomia (abdominal circumfer-
ence above the 70th centile).
 Tailor hypoglycaemic therapy for women with
gestational diabetes to the glycaemic profile of
and acceptability to the individual woman (hypo-
glycaemic therapy comprises one or more of:
regular insulin, the rapid acting insulin analogues
lispro and aspart, the hypoglycaemic agents
metformin and glibenclamide).
Antenatal care appointments
 Offer pregnant women with diabetes immediate
contact with a joint diabetes and antenatal clinic;
contact with the diabetes care team for assess-
ment of glycaemic control should occur every
one to two weeks; antenatal appointments should
cover care specifically for women with diabetes in
addition to the care provided routinely for
healthy pregnant women.
 Prioritise women with diabetes for examination
of the four chamber view of the fetal heart and
outflow tracts at 18-20 weeks.
Preterm labour in women with diabetes
 Antenatal steroids for fetal lung maturation are
not contraindicated but should be administered
with additional insulin in women with insulin
treated diabetes.
 Tocolysis is not contraindicated, but do not use
betamimetics for tocolysis in women with diabetes.
Timing and mode of birth
 Offer an anaesthetic assessment in the third
trimester to women with comorbidities such as
obesity or autonomic neuropathy; if general
anaesthesia is used for the birth, monitor blood
glucose every 30 minutes from induction of
Effects of diabetes on pregnancy and effects of pregnancy on diabetes
Information and advice for women with diabetes and their families should cover the
following points
 The role of diet, weight, and exercise (includingweight loss advice for womenwho have a
body mass index (kg/m2) above 27)
 The increased risk of having a baby who is large for gestational age, increasing the
likelihood of birth trauma, induction of labour, and caesarean section
 The importanceofmaternal glycaemic control during labour andbirth andearly feedingof
the baby to reduce the risk of neonatal hypoglycaemia
 The possibility of transient morbidity (such as hypoglycaemia or respiratory distress
syndrome) in the baby during the neonatal period, which may require admission to a
neonatal unit
 The risk of the baby developing obesity and/or diabetes in later life
For women with pre-existing diabetes information and advice should also cover the
following points
 The need for folic acid supplementation (5 mg a day) until 12 weeks’ gestation to reduce
the risk of having a baby with a neural tube defect
 The risksofhypoglycaemiaandofhypoglycaemiaunawarenessduringpregnancyand the
effects of nausea and vomiting during pregnancy on glycaemic control
 The need for assessment of diabetic retinopathy and nephropathy before and/or during
pregnancy.
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general anaesthesia until after the baby is born
and the woman is fully conscious.
 Offer elective birth after 38 completed weeks
(induction of labour or, if indicated, elective
caesarean section); inform women who have a
macrosomic fetus that has been diagnosed with
ultrasound about the risks and benefits of vaginal
birth, induction of labour, and caesarean section.
Glycaemic control during labour and birth
 Monitor capillary blood glucose hourly during
labour and birth to maintain a concentration
between 4 mmol/l and 7 mmol/l; if the concen-
tration is not maintained in this range, use
intravenous dextrose and insulin infusion during
labour and birth.
 In women with type 1 diabetes, consider intra-
venous dextrose and insulin infusion from the
onset of labour.
Initial assessment and care of the newborn baby
 Advise women to give birth in hospitals where
advanced neonatal resuscitation skills are avail-
able 24 hours a day; keep babies with their
mothers unless a clinical complication or abnor-
mal clinical signs arise that warrant admission for
intensive or special care.
 Feed babies as soon as possible after birth (within
30 minutes) and then every two to three hours
until feeding maintains prefeed blood glucose
concentrations of at least 2.0 mmol/l. Test blood
glucose concentrations at two to four hours after
birth. Only if concentrations are below
2.0 mmol/l on two consecutive readings despite
maximal support for feeding, or if there are
abnormal clinical signs, or if the baby will not
feed orally effectively, should additional mea-
sures such as tube feeding or intravenous
dextrose should be given. Test blood glucose in
babies who present with clinical signs of hypo-
glycaemia (such as abnormal muscle tone or level
of consciousness, fits, apnoea) and start treatment
with intravenous dextrose as soon as possible.
 Perform echocardiography for babies who show
clinical signs associated with congenital heart
disease (including heart murmur) or cardio-
myopathy.
 Do not test for polycythaemia, hyperbilirubinae-
mia, hypocalcaemia, or hypomagnesaemia unless
the baby has clinical signs.
 Recognise criteria for admission to a neonatal
unit, such as hypoglycaemia associated with
abnormal clinical signs, respiratory distress,
signs of cardiac decompensation, or neonatal
encephalopathy.
Postnatal management of diabetes
Pre-existing diabetes
 Reduce insulin immediately after the birth in
women with insulin treated pre-existing diabetes.
Monitor blood glucose levels carefully to estab-
lish the appropriate dose, and inform women of
the increased risk of hypoglycaemia in the
postnatal period, especially if breast feeding
(when a meal or snack before or during feeds is
advisable).
 Resume (or continue) use of metformin and
glibenclamide immediately after birth in women
with pre-existing type 2 diabetes who are breast
feeding.
 Continue to avoid any drugs for treating diabetes
complications that were discontinued for safety
reasons in the pre-conception period.
 Refer women with pre-existing diabetes back to
their routine diabetes care arrangements; remind
them of the importance of contraception and the
need for preconception care when planning
future pregnancies.
Gestational diabetes
 Discontinue hypoglycaemic therapy immediately
after the birth in women who were diagnosed
with gestational diabetes; test their blood glucose
to exclude persisting hyperglycaemia before
transfer to community care, and remind them of
the symptoms of hyperglycaemia.
 Offer lifestyle advice (on weight control, diet, and
exercise) and a fasting plasma glucose measure-
ment (but not an OGTT) at the six week postnatal
check and annually thereafter.
 Provide information about the risk of gestational
diabetes in future pregnancies, offer screening for
diabetes when planning future pregnancies, and
offer early self monitoring of blood glucose or an
OGTT in future pregnancies.
Overcoming barriers
This guidance for care of women with diabetes and
their families aims to empower them so that
pregnancy and child birth are positive experiences.
For example, uptake of preconception care is
encouraged by using every contact with healthcare
professionals (including the diabetes care team) to
inform women of childbearing age about the benefits
of preconception glycaemic control and every con-
tact with the diabetes care team to document
intentions about pregnancy and contraceptive use,
and by also giving preconception care in a supportive
environment, with the woman’s partner or other
family members encouraged to attend. Other recom-
mendations aim to prepare women for the additional
time and effort required to manage diabetes during
pregnancy and to provide maximal support for
women who wish to breast feed.
To support implementation,NICEand theguideline
development group have developed a version of the
guidance (available at www.nice.org.uk/CG063Publi
cInfoEnglish) that can be given to women with pre-
existing diabetes, women who are planning to become
pregnant, and women’s partners or families.
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Commentary: Controversies in management of diabetes
from preconception to the postnatal period
Lucy C Chappell,1 Sarah J Germain2
Why does the United Kingdom remain so far from
achieving the aim of “a pregnancy outcome for women
with diabetes that equates with that of women without
diabetes,” an aim outlined at the landmark St Vincent
meeting of diabetes experts, government representa-
tives, and patient organisations nearly 20 years ago?1
Pregnancy outcomes in the UK continue to be
substantially worse for women with pre-existing
diabetes (both type 1 and type 2), with rates of
congenital anomalies and perinatal mortality signifi-
cantly higher than in non-diabetic women and with
care regularly falling short of the required standard.2
Many of the recommendations in the new guidelines
from the National Institute for Health and Clinical
Excellence (NICE) seem sensible and will be of use to
all healthcare professionals in this area, but in places
they are surprisingly clear cut given the relativepaucity
of high quality evidence.
Theguidelines suggest a comprehensiveprogramme
of care from preconception to postnatal management.
They include a strong emphasis on preparation for
pregnancy, which requires considerable involvement
of general practitioners, diabetologists, specialist
obstetricians and midwives, and most importantly the
women themselves. This message has been echoed by
the latest triennial maternal mortality report from the
UK, which highlights the importance of joined-up care
for such women.3 Given that two thirds of pregnant
women with pre-existing diabetes had a haemoglobin
A1C concentration greater than 7% in the first trimester
(the threshold for optimal glycaemic control in the
report from the Confidential Enquiry into Maternal
and Child Health),2 achieving the recommendation of
aiming to “maintain a HbA1C below 6.1%” seems
particularly optimistic. Much greater uptake of struc-
tured education programmes and use of continuous
subcutaneous insulin infusion pumps, as shown to be
beneficial outside pregnancy, may need to be con-
sidered to achieve these tough targets. The resource
implications should not be underestimated,
particularly when those with poorest control may find
it hardest to access and use health care.
The recommendation that screening for gesta-
tional diabetes should be by clinical risk factor
alone is more controversial. The authors acknowl-
edge the poor sensitivity and specificity of this
approach compared with universal administration
of oral glucose tolerance tests. In some groups, use of
clinical risk factorsmisses nearly half thewomenwith
gestational diabetes,4 but the performance of this
screening method will depend on the maternal age,
ethnicity, and body mass index profile of each
population.As theACHOIS trial5 provided evidence
of potential benefit for treatment of even mild
gestational diabetes, missing a substantial proportion
of cases of gestational diabetes may translate into
clinical detriment. The ongoing hyperglycaemia and
pregnancy outcome trial (which is assessing associa-
tions of maternal glycaemia with risks of adverse
pregnancy outcome) will clarify further the need for
treatment in thismilder group.On a positive note, the
option to use metformin for the treatment of
gestational and type 2 diabetes will be welcomed as
an alternative or addition to insulin.
Obstetricians may be surprised, given the limited
evidence, at the recommendation to offer delivery to all
women with diabetes at 38 weeks’ gestation as this will
represent a change in clinical practice for many. It
reflects the difficulty with which late pregnancy compli-
cations, particularly shoulder dystocia and stillbirth, can
be predicted. Women with diabetes already have a
caesarean section rateof 60-70%, three timeshigher than
the rate in the general population ofwomengiving birth;
the debate continues about themost appropriate rate for
caesarean section indiabeticwomen, given the short and
long term risks of this procedure, particularly in obese
women. Optimising glycaemic control to prevent
macrosomia and understanding the mechanism by
which diabetes increases the risk of stillbirth may be
more thoughtful approaches in the long term.
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